Market Closed -
Nasdaq
21:30:00 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
13.16
USD
|
-2.95%
|
|
+5.70%
|
-12.79%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
534.4
|
423.7
|
503
|
426.5
|
-
|
-
|
Enterprise Value (EV)
1 |
243.3
|
378.5
|
503
|
342
|
317
|
308.1
|
P/E ratio
|
-2.1
x
|
-4.48
x
|
-75.5
x
|
-5.75
x
|
-4.01
x
|
-3.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
3.9
x
|
6.89
x
|
14.9
x
|
18.8
x
|
EV / Revenue
|
-
|
-
|
3.9
x
|
5.52
x
|
11.1
x
|
13.6
x
|
EV / EBITDA
|
-4.87
x
|
-3.97
x
|
-1,567
x
|
-2.72
x
|
-1.93
x
|
-1.76
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
31,213
|
31,338
|
33,334
|
32,409
|
-
|
-
|
Reference price
2 |
17.12
|
13.52
|
15.09
|
13.16
|
13.16
|
13.16
|
Announcement Date
|
15/03/22
|
06/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
129
|
61.91
|
28.63
|
22.7
|
EBITDA
1 |
-
|
-50.01
|
-95.35
|
-0.321
|
-125.6
|
-164.4
|
-174.8
|
EBIT
1 |
-
|
-51.13
|
-97.25
|
-3.162
|
-79.92
|
-137.4
|
-154.3
|
Operating Margin
|
-
|
-
|
-
|
-2.45%
|
-129.09%
|
-479.78%
|
-679.61%
|
Earnings before Tax (EBT)
1 |
-
|
-51.16
|
-94.62
|
12.06
|
-79.91
|
-136.4
|
-164
|
Net income
1 |
-26.52
|
-51.16
|
-94.62
|
-6.685
|
-81.89
|
-139.1
|
-164
|
Net margin
|
-
|
-
|
-
|
-5.18%
|
-132.28%
|
-485.63%
|
-722.35%
|
EPS
2 |
-3.320
|
-8.160
|
-3.020
|
-0.2000
|
-2.290
|
-3.283
|
-3.590
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/08/21
|
15/03/22
|
06/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
25.26
|
18.17
|
43.74
|
41.85
|
15.19
|
16.44
|
15.19
|
16.44
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.36
|
-18.46
|
-22.15
|
-23.58
|
-25.94
|
-25.58
|
-5.78
|
-16.3
|
14.01
|
4.905
|
-16.63
|
-17.23
|
-21.08
|
-18.45
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-22.88%
|
-89.7%
|
32.04%
|
11.72%
|
-109.43%
|
-104.78%
|
-138.71%
|
-112.22%
|
-
|
Earnings before Tax (EBT)
1 |
-14.43
|
-18.45
|
-21.67
|
-23.18
|
-25.14
|
-24.63
|
-3.123
|
-12.08
|
18.06
|
9.197
|
-17.2
|
-17.17
|
-20.83
|
-19.43
|
-
|
Net income
1 |
-14.43
|
-18.45
|
-21.67
|
-23.18
|
-25.14
|
-24.63
|
-6.674
|
-25.93
|
35.46
|
-9.544
|
-17.2
|
-17.17
|
-20.83
|
-19.43
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-26.42%
|
-142.7%
|
81.08%
|
-22.81%
|
-113.2%
|
-104.39%
|
-137.11%
|
-118.18%
|
-
|
EPS
2 |
-9.780
|
-0.8900
|
-0.6900
|
-0.7400
|
-0.8000
|
-0.7800
|
-0.2100
|
-0.7800
|
1.020
|
-0.2800
|
-0.5600
|
-0.5250
|
-0.6150
|
-0.5875
|
-0.6900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/12/21
|
15/03/22
|
12/05/22
|
11/08/22
|
07/11/22
|
06/03/23
|
10/05/23
|
08/08/23
|
07/11/23
|
13/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
291
|
45.2
|
-
|
84.5
|
110
|
118
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
2.89
|
-
|
6.5
|
7
|
7.5
|
Capex / Sales
|
-
|
-
|
-
|
-
|
10.5%
|
24.45%
|
33.03%
|
Announcement Date
|
06/08/21
|
15/03/22
|
06/03/23
|
13/03/24
|
-
|
-
|
-
|
Last Close Price
13.16
USD Average target price
21
USD Spread / Average Target +59.57% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.79% | 427M | | +8.96% | 105B | | -1.43% | 104B | | +5.24% | 22.94B | | -12.15% | 22.34B | | -6.40% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|